natgillin/translations-raw huggingface dataset:
The efficacy data from study GS-US-264-0111 (see section 5.1) indicates that the brief period of lower rilpivirine exposure does not impact antiviral efficacy of Eviplera. 
Podatki o učinkovitosti iz študije GS-US-264-0111 (glejte poglavje 5.1) kažejo, da kratka obdobja nižje izpostavljenosti rilpivirinu ne vplivajo na protivirusno učinkovitost zdravila Eviplera.
Resistance to emtricitabine/lamivudine (M184I/V) 
Rezistenca na emtricitabin/lamivudin (M184I/V)
The terminal elimination half-life of rilpivirine is approximately 45 hours. 
Končna razpolovna doba rilpivirina je približno 45 ur.
• If you have taken Eviplera during your pregnancy, your doctor may request regular blood tests and other diagnostic tests to monitor the development of your child. 
• Če ste zdravilo Eviplera jemali med nosečnostjo, vas lahko zdravnik naroči na redne preiskave krvi in druge diagnostične preiskave, da bo spremljal razvoj vašega otroka.
Alternatively, switching to another antiretroviral regimen could be considered (see sections 4.4, 4.6, 5.1 and 5.2). 
Druga možnost je, da se razmisli o prehodu na drug protiretrovirusni režim (glejte poglavja 4.4, 4.6, 5.1 in 5.2).
Due to the decline in efavirenz plasma levels, the inductive effect decreased and rilpivirine concentrations started to normalise. 
Zaradi zmanjšanja ravni efavirenza v plazmi se je induktivni učinek zmanjšal in koncentracije rilpivirina so se začele normalizirati.
• Rifabutin, a medicine to treat some bacterial infections. 
• Rifabutin, zdravilo, ki se uporablja za zdravljenje nekaterih bakterijskih okužb.
• Increased levels of creatine kinase in the blood that may result in muscle pain and weakness 
• povišane ravni kreatin kinaze v krvi, ki lahko povzročijo bolečine in oslabelost mišic
Talk to your doctor about an alternative regimen (see section 3, How to take Eviplera). 
Z zdravnikom se pogovorite o alternativnem režimu (glejte poglavje 3, Kako jemati zdravilo Eviplera).
Insufficient safety data are available for children under the age of 18 years. 
Za otroke stare do 18 let so podatki o varnosti nezadostni.
• Difficulty sleeping (insomnia) 
• težave s spanjem (nespečnost)
Your doctor will discuss a different medicine if required. 
Vaš zdravnik se bo po potrebi z vami dogovoril za drugo zdravilo.
The E138K substitution emerged most frequently during rilpivirine treatment, commonly in combination with the M184I substitution. 
Substitucija E138K se je najpogosteje pojavila pri zdravljenju z rilpivirinom, pogosto v kombinaciji s substitucijo M184I.
In the studies, the presence of the mutations V90I and V189I at baseline did not affect the response. 
V študijah prisotnost mutacij V90I in V189I na začetku ni vplivala na odziv.
This is partly linked to restored health and life style, and in the case of blood lipids sometimes to the HIV medicines themselves. 
To je lahko deloma povezano z obnovljenim zdravjem in življenjskim slogom, pri krvnih lipidih pa občasno tudi s samimi zdravili za zdravljenje okužbe z virusom HIV.
Maximum tenofovir concentrations are observed in plasma within 2 hours and maximum plasma concentrations of rilpivirine are generally achieved within 4-5 hours. 
Največje koncentracije tenofovira so opazili v plazmi v roku 2 ur in največje koncentracije rilpivirina v plazmi so običajno dosežene v roku 4-5 ur.
Do not chew, crush or split the tablet - if you do it may affect the way the medicine is released into your body. 
Tablete ne žvečite, drobite ali delite - to lahko vpliva na način sproščanja zdravila v vašem telesu.
It is not considered to be causally associated with tenofovir disoproxil in the absence of this condition. 
Ne smatra se kot vzročno povezan z dizoproksiltenofoviromat v odsotnosti tega stanja.
• Damage to kidney tubule cells 
• poškodbe celic ledvičnih tubulov
In dogs cholestasis-like effects were noted. 
Pri psih so opazili učinke, podobne holestazi.
The safety and efficacy of Eviplera in children under the age of 18 years have not been established. 
Varnost in učinkovitost zdravila Eviplera pri otrocih, starih pod 18 let, nista bili dokazani.
However, clinical monitoring is recommended as methadone maintenance therapy may need to be adjusted in some patients. 
Vendar pa se priporoča klinično spremljanje, saj je morda pri nekaterih bolnikih treba prilagoditi vzdrževalno zdravljenje z metadonom.
The EC50 values for tenofovir were in the range of 0.04 to 8.5 µM. 
Vrednosti EC50 za tenofovir so bile v razponu 0,04 do 8,5 µM.
Other effects that may be seen during HIV treatment 
Drugi možni neželeni učinki, ki se lahko pojavijo med zdravljenjem okužbe z virusom HIV
e e.g. lost to follow up, non-compliance, withdrew consent. 
e Npr. izgubljeni za spremljanje, neskladnost, umik soglasja.
The 50% effective concentration (EC50) values for emtricitabine were in the range of 0.0013 to 0.64 µM. 
Vrednosti s 50-odstotno učinkovito koncentracijo (EC50) za emtricitabin so bile v razponu od 0,0013 do 0,64 µM.
There is not sufficient data to justify the use in patients with prior NNRTI failure. 
Podatki ne zadoščajo za utemeljitev uporabe pri bolnikih s predhodno odpovedjo NNRTI.
Possible side effects: tell a doctor immediately 
Možni neželeni učinki: takoj obvestite zdravnika
Do not drive or operate machines if you feel tired, sleepy or dizzy after taking your medicine. 
Ne vozite avtomobila in ne upravljajte strojev, če ste po uporabi zdravila utrujeni, zaspani ali omotični.
Tell your doctor if you are taking any of the following: 
Obvestite zdravnika, če uporabljate kaj od naslednjega:
• Lactic acidosis (excess lactic acid in the blood) is a rare but potentially life-threatening side effect of some HIV medicines. 
• Laktacidoza (preveč mlečne kisline v krvi) je redek, a življenjsko nevaren neželeni učinek pri nekaterih zdravilih za zdravljenje HIV.
However, it may not be excluded that the pharmacologically active, unbound, rilpivirine exposure is significantly increased in moderate impairment. 
Vendar pa ni mogoče izključiti, da se izpostavitev farmakološko aktivnemu, nevezanemu rilpivirinu pomembno poveča pri zmerni okvari.
If you are taking one of these medicines your doctor will either give you a different medicine for stomach ulcers, heartburn or acid reflux, or recommend how and when you take that medicine. 
Če jemljete ta zdravila, vam bo zdravnik dal drugo zdravilo za razjede želodca, zgago ali refluks kisline ali priporočal, kako in kdaj naj zdravilo vzamete.
Not enough patients over the age of 65 
Niso preučili dovolj bolnikov, starejših od 65 let.
Both emtricitabine and tenofovir have activity that is specific to HIV-1, HIV-2 and, HBV. 
Tako emtricitabin kot tenofovir imata aktivnost, ki je specifična za HIV-1, HIV-2 in HBV.
De novo resistance to emtricitabine/lamivudine was seen in 4 cases, and also to rilpivirine in 2 cases, with a consequent cross-resistance to efavirenz (2/2), nevirapine (2/2) and etravirine (1/2). 
Na novo nastalo rezistenco na emtricitabin/lamivudin so opazili v 4 primerih in tudi na rilpivirin v 2 primerih, s posledično navzkrižno rezistenco na efavirenz (2/2), nevirapin (2/2) in etravirin (1/2).
• Talk to your doctor if you have a history of liver disease, including hepatitis. 
• Obvestite zdravnika, če imate jetrne bolezni v anamnezi, vključno s hepatitisom.
The most common mutations were the same in the week 48 and week 96 analyses. 
Najpogostejše mutacije so bile v analizah 48. tedna in 96. tedna enake.
Population pharmacokinetic analysis in HIV infected patients showed that rilpivirine pharmacokinetics is not different across the age range (18 to 78 years) evaluated, with only 2 patients aged 65 years of age or older. 
Populacijska farmakokinetična analiza bolnikov, okuženih z virusom HIV, je pokazala, da se farmakokinetika rilpivirina ne razlikuje glede na razpon ocenjene starosti (18 do 78 let), s samo 2 bolnikoma, starima 65 let ali več.
It is important not to stop taking Eviplera without talking to your doctor: see section 3, Do not stop taking Eviplera. 
Pomembno je, da zdravila Eviplera ne prenehate jemati, ne da se pogovorite z zdravnikom: glejte poglavje 3, Ne prenehajte jemati zdravila Eviplera.
The studies are identical in design with the exception of the background regimen (BR). 
Te študije so po zasnovi identične in se razlikujejo le po osnovni shemi zdravljenja (background regimen, BR).
Your doctor may do blood tests to see if your kidneys are working properly 
Vaš zdravnik lahko opravi krvne preiskave, da ugotovi, ali vaše ledvice dobro delujejo
QT prolonging medicinal products 
Zdravila, ki podaljšujejo QT
hepatitis3, hepatic steatosis3 
hepatitis3, hepatična steatoza3
If you have HIV infection and hepatitis B, it is especially important not to stop your Eviplera treatment without talking to your doctor first. 
Če ste okuženi z virusom HIV in hepatitisom B, je še zlasti pomembno, da ne prenehate z zdravljenjem z zdravilom Eviplera, ne da bi se prej posvetovali z zdravnikom.
• Increased levels of cholesterol and/or pancreatic amylase in the blood 
• povišane ravni holesterola in/ali pankreasne amilaze v krvi
• Dabigatran etexilate, a medicine used to treat heart conditions, as your doctor may need to monitor the levels of this medicine in your blood. 
• Dabigatran eteksilat, zdravilo, ki se uporablja za zdravljenje bolezni srca, saj bo moral zdravnik morda nadzirati ravni tega zdravila v vaši krvi.
The oral bioavailability of tenofovir from tenofovir disoproxil tablets in fasted patients was approximately 25%. 
Peroralna biološka uporabnost tenofovirja iz tablet dizoproksiltenofovirata pri bolnikih na tešče je bila približno 25 %.
• Tell your doctor immediately and stop taking Eviplera if you develop a skin rash with the following symptoms: fever, blisters, redness in your eyes and swelling of your face, mouth or body. 
• Takoj obvestite zdravnika in prenehajte jemati zdravilo Eviplera, če se pojavi kožni izpuščaj z naslednjimi simptomi: zvišana telesna temperatura, mehurji, rdečina v očeh in oteklost obraza, ust ali telesa.
In some cases, your doctor may need to adjust your dose or check your blood levels. 
V nekaterih primerih bo moral zdravnik prilagoditi vaš odmerek ali opraviti preiskave ravni v krvi.
Switching from an efavirenz-based regimen 
Prehod z režima na podlagi efavirenza
• Problems with digestion resulting in discomfort after meals, wind (flatulence) 
• težave s prebavo, ki privedejo do slabega počutja po zaužitem obroku, vetrovi (flatulenca)
• Softening of the bones (with bone pain and sometimes resulting in fractures) 
• mehčanje kosti (z bolečinami v kosteh, včasih tudi zlom)
The recommended dose of Eviplera is one tablet, taken orally, once daily. 
Priporočeni odmerek zdravila Eviplera je ena tableta, peroralno, enkrat dnevno.
Tenofovir is primarily excreted by the kidney by both filtration and an active tubular transport system (human organic anion transporter 1 [hOAT1]) with approximately 70-80% of the dose excreted unchanged in urine following intravenous administration. 
Tenofovir se primarno izloča preko ledvic tako s filtracijo kot z aktivnim tubularnim transportnim sistemom (humani prenašalec organskih anionov 1 [hOAT1]), pri čemer se po intravenskem vnosu približno 70-80 % odmerka izloči nespremenjenega z urinom.
Rilpivirine was well tolerated during pregnancy and postpartum. 
Bolnice so rilpivirin dobro prenašale med nosečnostjo in po porodu.
Carcinogenicity studies with rilpivirine in mice and rats revealed tumorigenic potential specific for these species, but are regarded as of no relevance for humans. 
Študije kancerogenosti z rilpivirinom pri miših in podganah so razkrile tumorogeni potencial, specifičen za te vrste, za katerega velja, da za ljudi ni pomemben.
It is recommended that Eviplera be swallowed whole with water. 
Priporočljivo je, da se zdravilo Eviplera pogoltne celo z vodo.
Your doctor may need to give you an additional dose of rilpivirine to treat your HIV infection (see section 3, How to take Eviplera). 
Vaš zdravnik vam bo morda moral dati dodatni odmerek rilpivirina za zdravljenje vaše okužbe s HIV (glejte poglavje 3, Kako jemati zdravilo Eviplera).
• H2-antagonists (famotidine, cimetidine, nizatidine or ranitidine) These medicines can decrease the amount of rilpivirine (a component of Eviplera) in your blood. 
• antagonisti H2 (famotidin, cimetidin, nizatidin ali ranitidin) Ta zdravila lahko zmanjšajo količino rilpivirina (sestavina zdravila Eviplera) v vaši krvi.
The absolute bioavailability of rilpivirine is unknown. 
Absolutna biološka uporabnost rilpivirina ni znana.
• Medicines containing didanosine (for HIV infection): Taking Eviplera with other antiviral medicines that contain didanosine can raise the levels of didanosine in your blood and may reduce CD4+ cell counts. 
• Zdravila, ki vsebujejo didanozin (za okužbe z virusom HIV): Jemanje zdravila Eviplera z drugimi protivirusnimi zdravili, ki vsebujejo didanozin, lahko zviša nivoje didanozina v krvi in zmanjša število celic CD4+.
The efficacy of Eviplera is based on the analyses of 96 week data from two randomised, double-blind, controlled studies C209 and C215. 
Učinkovitost zdravila Eviplera temelji na analizah podatkov 96 tednov iz dveh randomiziranih, dvojno slepih, kontroliranih študij C209 in C215.
Eviplera contains three active substances that are used to treat Human Immunodeficiency Virus (HIV) infection: 
Zdravilo Eviplera vsebuje tri učinkovine, ki se uporabljajo za zdravljenje okužbe z virusom človeške imunske pomanjkljivosti (HIV):
The European Medicines Agency has waived the obligation to submit the results of studies with Eviplera in all subsets of the paediatric population in the treatment of HIV-1 (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z zdravilom Eviplera za vse podskupine pediatrične populacije za zdravljenje okužbe z virusom HIV-1 (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
The pharmacokinetic data demonstrate that total exposure (AUC) to rilpivirine as a part of an antiretroviral regimen was approximately 30% lower during pregnancy compared with postpartum (6-12 weeks). 
Farmakokinetični podatki kažejo, da je bila skupna izpostavljenost (AUC) rilpivirinu kot del protiretrovirusnega režima približno 30 % nižja med nosečnostjo v primerjavi z obdobjem po porodu (6-12 tednov).
The virologic response was generally preserved throughout the study: of the 12 patients that completed the study, 10 patients were suppressed at the end of the study; in the other 2 patients an increase in viral load was observed only postpartum, for at least 1 patient due to suspected suboptimal adherence. 
Virološki odziv je bil v celotni študiji na splošno ohranjen: od 12 bolnic, ki so zaključile študijo, je imelo na koncu študije supresijo 10 bolnic; pri drugih 2 bolnicah pa so povišanje virusne obremenitve opazili samo v obdobju po nosečnosti, pri čemer je bil pri najmanj 1 bolnici razlog domnevno neoptimalno sodelovanje z zdravljenjem.
52% of patients with virologic failure in the rilpivirine arm developed concomitant NNRTI and NRTI mutations. 
52 % bolnikov z virološkim neuspehom v kraku z rilpivirinom je razvilo sočasne mutacije NNRTI in NRTI.
5 Study conducted with additional voxilaprevir 100 mg to achieve voxilaprevir exposures expected in hepatitis C virus 
5 Študijo so izvedli z dodatnim voksilaprevirjem 100 mg za doseganje izpostavljenosti voksilaprevirju, ki se pričakuje pri bolnikih z okužbo z virusom hepatitisa C (HCV).
Lactic acidosis occurs more often in women - particularly if they are overweight, and in people with liver disease. 
Laktacidoza se pogosteje pojavi pri ženskah, zlasti tistih s prekomerno telesno maso in pri ljudeh z jetrno boleznijo.
However, it may not be completely excluded that rilpivirine can increase the exposure to other medicinal products transported by P-gp that are more sensitive to intestinal P-gp inhibition (e.g. dabigatran etexilate). 
Vendar pa ni mogoče povsem izključiti, da lahko rilpivirin zviša izpostavljenost drugim zdravilom, ki jih prenaša P-gp in so bolj občutljiva na zaviranje črevesnega P-gp (npr. dabigatran eteksilat).
The decrease in the unbound free fraction of rilpivirine exposure (i.e. active) during pregnancy compared to postpartum was less pronounced than for total exposure of rilpivirine. 
Zmanjšanje izpostavljenosti nevezani prosti frakciji rilpivirina (tj. aktivna) med nosečnostjo je bilo v primerjavi s poporodnim obdobjem manj izraženo kot za skupno izpostavljenost rilpivirinu.
The triple combination of emtricitabine, rilpivirine, and tenofovir demonstrated synergistic antiviral activity in cell culture. 
Pri trojni kombinaciji emtricitabina, rilpivirina in tenofovirja je bila dokazana sinergistična protivirusna aktivnost v celični kulturi.
• Increased fatty acids (triglycerides), bilirubin or sugar in the blood 
• povišanje maščobnih kislin (trigliceridov), bilirubina ali sladkorja v krvi
Treatment with Eviplera resulted in an early small increase of mean serum creatinine levels which remained stable over time and is not considered clinically relevant (see section 4.8). 
Zdravljenje z zdravilom Eviplera je povzročilo zgodnje majhno povečanje povprečnih ravni kreatinina v serumu, ki so ostale stabilne, zato se ne obravnavajo kot klinično pomembne (glejte poglavje 4.8).
AUC: ↑ Cmax: ↑ Cmin: ↑ 
tenofovir: AUC: ↑ Cmax: ↑ Cmin: ↑
If Eviplera for any reason is stopped, speak to your doctor before you restart taking Eviplera tablets. 
Če zaradi katerega koli razloga prenehate jemati zdravilo Eviplera, se pogovorite z zdravnikom, preden začnete ponovno jemati tablete zdravila Eviplera.
• Methadone, a medicine used to treat opiate addiction, as your doctor may need to change your methadone dose. 
• Metadon, zdravilo, ki se uporablja za zdravljenje zasvojenosti z opiati, saj bo moral zdravnik morda prilagoditi vaš odmerek metadona.
The breakdown of muscle, softening of the bones (with bone pain and sometimes resulting in fractures), muscle pain, muscle weakness and decreases in potassium or phosphate in the blood may occur due to damage to kidney tubule cells. 
Razpad mišičnega tkiva, mehčanje kosti (z bolečinami v kosteh, kar včasih vodi v zlom), bolečine v mišicah, mišična oslabelost in zmanjšanje količine kalija ali fosfatov v krvi se lahko pojavijo zaradi poškodbe celic ledvičnih tubulov.
The incidence of virologic failure was higher in the rilpivirine arm than in the efavirenz arm at week 96; however, most of the virologic failures occurred within the first 48 weeks of treatment. 
Incidenca virološkega neuspeha je bila v 96. tednu višja v kraku z rilpivirinom, kot v kraku z efavirenzom; vendar pa se je večina viroloških neuspehov pojavila v prvih 48 tednih zdravljenja.
During the time period of declining efavirenz plasma levels and increasing rilpivirine plasma levels after switching, none of the patients had efavirenz or rilpivirine levels below their respective IC90 levels at the same time. 
V obdobju upadanja ravni efavirenza v plazmi in povečevanja ravni rilpivirina v plazmi po prehodu ni imel noben od bolnikov ravni efavirenza ali rilpivirina pod vsakokratnimi ravnmi IC90 sočasno.
hypokalaemia3, 5 
hipokaliemija3, 5
e Includes patients who discontinued for reasons other than an AE, death or lack or loss of efficacy, e.g., withdrew consent, loss to follow-up, etc. 
e Vključuje bolnike, ki so sodelovanje prekinili zaradi drugih razlogov, kot so neželeni učinki, smrt ali pomanjkanje ali izguba učinka, npr. umik soglasja, izgubljeni za spremljanje itd.
Only trace amounts of unchanged rilpivirine (< 1% of dose) were detected in urine. 
V urinu so bili odkriti le sledovi nespremenjenega rilpivirina (< 1 % odmerka).
Population pharmacokinetic analysis indicated that hepatitis B and/or C virus co-infection had no clinically relevant effect on the exposure to rilpivirine. 
Populacijska farmakokinetična analiza je pokazala, da sočasna okužba z virusom hepatitisa B in/ali C nima klinično pomembnega učinka na izpostavljenost rilpivirinu.
If overdose occurs the patient must be monitored for evidence of toxicity (see section 4.8), and standard supportive treatment applied as necessary including observation of the clinical status of the patient and monitoring of vital signs and ECG (QT interval). 
V primeru prevelikega odmerka je potrebno pri bolniku nadzorovati znake toksičnosti (glejte poglavje 4.8) in mu nuditi standardno podporno zdravljenje, vključno z opazovanjem kliničnega stanja bolnika in nadziranjem vitalnih znakov in EKG-ja (interval QT).
Macrolide antibiotics Clarithromycin Erythromycin 
Makrolidni antibiotiki klaritromicin eritromicin
• Tell your doctor if you had kidney disease, or if tests have shown kidney problems. 
• Obvestite zdravnika, če ste imeli težave z ledvicami ali če so preiskave pokazale, da imate težave z ledvicami.
No clinically relevant drug-drug interaction is expected. 
Klinično pomembnih interakcij zdravil se ne pričakuje.
Eviplera is not usually taken with other medicines that can damage your kidneys (see Other medicines and Eviplera). 
Zdravila Eviplera se ponavadi ne jemlje z drugimi zdravili, ki bi lahko poškodovala ledvice (glejte Druga zdravila in zdravilo Eviplera).
A negative impact by NNRTI mutations other than those listed above (e.g. mutations K103N or L100I as single mutations) cannot be excluded, since this was not studied in vivo in a sufficient number of patients. 
Drugega negativnega vpliva mutacij NNRTI, razen zgoraj navedenih (npr. mutacije K103N ali L100I kot samostojni mutaciji) ni mogoče izključiti, saj študije in vivo niso bile izvedene pri zadostnem številu bolnikov.
This may result in loss of therapeutic effect of Eviplera (see section 4.3). 
To lahko povzroči izgubo terapevtskega učinka zdravila Eviplera (glejte poglavje 4.3).
• Low white blood cell count (a reduced white blood cell count can make you more prone to infection) 
• nizko število belih krvnih celic (zmanjšanje števila belih krvnih celic lahko povzroči večjo nagnjenost k okužbam)
In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant Summary of Product Characteristics for these medicinal products. 
V primeru spremljajoče protivirusne terapije hepatitisa B ali C upoštevajte tudi ustrezne povzetke glavnih značilnosti teh zdravil.
2 Phenotypic resistance to rilpivirine (> 3.7-fold change compared to control). 
1 Fenotipska rezistenca na rilpivirin (> 3,7-kratna sprememba glede na kontrolo).
The increased exposure of tenofovir could potentiate adverse reactions associated with tenofovir disoproxil, including renal disorders. 
Večja izpostavljenost tenofovirju lahko potencira neželene reakcije, ki so povezane z dizoproksiltenofoviratom, vključujoč ledvične motnje.
The resistance outcome for patients with protocol defined virological failure and phenotypic resistance at week 96 are shown in Table 6: 
Izid rezistence za bolnike, ki imajo v protokolu definiran virološki neuspeh in fenotipsko rezistenco je prikazan v preglednici 6 za 96. teden:
In some patients with advanced HIV infection (AIDS) and a history of opportunistic infections (infections that occur in people with a weak immune system), signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started. 
Pri nekaterih bolnikih z napredovalo okužbu s HIV (AIDS-om) in oportunističnimi okužbami v anamnezi (okužbe, ki se pojavijo pri ljudeh z oslabljenim imunskim sistemom), se lahko znaki in simptomi vnetja zaradi prejšnjih okužb pojavijo kmalu po začetku zdravljenja HIV.
As a precautionary measure, it is preferable to avoid the use of Eviplera during pregnancy. 
Iz previdnosti se je med nosečnostjo bolje izogibati uporabi zdravila Eviplera.
Contact your doctor or nearest emergency department immediately for advice. 
Takoj se posvetujte z zdravnikom ali poiščite najbližjo urgentno ambulanto.
The difference in the rate of new virologic failures from the week 48 to week 96 analysis between rilpivirine and efavirenz arms was not statistically significant. 
Razlika v stopnji novih viroloških neuspehov v analizi od 48. do 96. tedna med krakoma z rilpivirinom in efavirenzom ni bila statistično značilna.